<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5167130 Figure_1-A-B-C</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 1-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>(A) 12-lead ECG of patient 1. (B) 12-lead ECG of patient 2. (C) ECG of patient 2 during epinephrine test (A- represents baseline ECG; B- ECG at 17 min and 47 s of the beginning of epinephrine infusion (0.2 &#956;g/kg of epinephrine) and C- ECG after the end of epinephrine infusion).</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_1-E</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) ECG of patient 3 (subject IV:13) showing mild QTc prolongation.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_1-F</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 1-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) ICD interrogation of patient 3 (subject IV:13) reveals an episode of VT.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_2-A-H</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 2-A-H</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-H</infon>
    <passage>
      <offset>0</offset>
      <text>(A-H) Expression of Tecrl in mouse development. Expression is not observed in (A) the cardiac crescent at E7.5 but is prominent in (B) the inflow tract (ift) region at E8.5, particularly in (C) the left sinus venosus (lsv). (D) At E9.5, Tecrl expression is observed in all four chambers of the heart but is strongest in the inflow tract. (E-G) From E10 onwards, Tecrl is expressed in the somites. (H) At E14.5, Tecrl expression is present in the entire myocardium; [atrium (a), ventricle (v), neural tube (nt), lung (lu), right atrium (ra), left atrium (la), right ventricle (rv) and left ventricle (lv)].</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_2-I</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 2-I</infon>
    <infon key="sourcedata_figure_dir">Figure_2-I</infon>
    <passage>
      <offset>0</offset>
      <text>(I) mRNA expression analyses of TECR and TECRL by RT-qPCR in human tissues demonstrates preferential expression of Tecrl in the heart; [Bone marrow (Bone M.), heart, skeletal muscle (Sk.Muscle), uterus, liver, spleen, thymus, thyroid, prostate, brain, lung, small intestine (Small I.) and colon]</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_2-J</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 2-J</infon>
    <infon key="sourcedata_figure_dir">Figure_2-J</infon>
    <passage>
      <offset>0</offset>
      <text>(J) Localization of MYC-Tecrl in COS-1 cells. The accumulation of MYC-Tecrl is perinuclear consistent with it being localized to the ER.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_2-K-L-M</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 2-K-L-M</infon>
    <infon key="sourcedata_figure_dir">Figure_2-K-L-M</infon>
    <passage>
      <offset>0</offset>
      <text>(K-M) Co-localization of MYC-Tecrl and the ER marker Calnexin in H10 cells. Nuclei stained with DAPI. Scale bar: 10 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_3-A</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Skin fibroblasts(left) from IV:13, homozygous for the TECRLc.331+1G&gt;A mutation were reprogrammed to hiPSCs(center), which expressed the pluripotency markers NANOG and SSEA4(right). Scale bars: 100 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_3-B</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) TECRLHom-hiPSCs have a normal karyotype(left) and PluriTest demonstrates a high pluripotency score and low novelty score for all three hiPSC lines (right).</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_3-C</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) TECRLHom-hiPSCs generate derivatives of mesoderm(left), endoderm(center) and ectoderm(right). Scale bars: 25 &#956;m</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_3-F</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 3-F</infon>
    <infon key="sourcedata_figure_dir">Figure_3-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) ACTN2 immunostaining of CTRL-, TECRLHet- and TECRLHom-hiPSC-CMs. Scale bar: 25 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_3-G</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 3-G</infon>
    <infon key="sourcedata_figure_dir">Figure_3-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) Analysis of RT-PCR products by gel electrophoresis. Amplification products of TECRL exons 2-4 from CTRL-, TECRLHet- and TECRLHom-hiPSC-CMs (left) and coding sequence of TECRL from CTRL- and TECRLHom-hiPSC-CMs (right).</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_4-A-B-C</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 4-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Representative traces of [Ca2+]i transients in Indo-1 AM-loaded hiPSC-CMs paced at 1 Hz. (B) Time to reach 50% of [Ca2+]i transient amplitude, t1/2; [Ca2+]i concentrations during systole and diastole (C) Amplitude and tau decay of the [Ca2+]i transient.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_5-A-B</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 5-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Representative traces of [Ca2+]i transients in Indo-1 AM-loaded hiPSC-CMs paced at 1 Hz, in the presence of caffeine (caff) or caffeine and NiCl2. (B) Amplitude of [Ca2+]i in the presence of caffeine and NiCl2and fractional SR release in hiPSC-CMs.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_5-C-D</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 5-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Rate constants of SERCA-, NCX- and slow mechanisms-based [Ca2+]i decay in hiPSC-CMs. (D) Relative contribution of SERCA, NCX and slow mechanisms to [Ca2+]i extrusion in hiPSC-CMs.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_6-A-B-C</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 6-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>(A) AP illustrating the analysed parameters (B) Representative APs from control (CTRL), heterozygous (HET) and homozygous (HOM) CMs. (C) RMP, dV/dtmax , APAmax, APAplat, APD20, APD50 and APD90 of CTRL-, TECRLHet- and TECRLHom-hiPSC-CMs.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_7-A-D</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 7-A-D</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A-D</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Representative AP traces and (B) averaged activity of triggered and spontaneous activity in hiPSC-CMs in the absence of NA. (C) Representative AP traces and (D) averaged activity of triggered and spontaneous activity in hiPSC-CMs in the presence of NA.</text>
    </passage>
  </document>
  <document>
    <id>5167130 Figure_8-A-D</id>
    <infon key="sourcedata_document">2421</infon>
    <infon key="doi">10.15252/emmm.201505719</infon>
    <infon key="pmc_id">5167130</infon>
    <infon key="figure">Figure 8-A-D</infon>
    <infon key="sourcedata_figure_dir">Figure_8-A-D</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Representative AP trace of a TECRLHom-hiPSC-CM in the presence of NA alone or NA and flecainide. (B) Effect of flecainide on AP parameters of hiPSC-CMs. (C-D) Addition of 5 &#956;M of flecainide decreased the susceptibility to triggered activity in hiPSC-CMs. Note that the effect of flecainide on triggered activity of TECRLHet- and TECRLHom-hiPSC-CMs is more pronounced than its effect on their spontaneous activity.</text>
    </passage>
  </document>
</collection>
